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Supressed levels of intracellular cAMP have been associated with malignancy. Thus, 
elevating cAMP through activation of adenylyl cyclase (AC) or by inhibition of 
phosphodiesterase (PDE) may be therapeutically beneficial. Here, we demonstrate 
that elevated cAMP levels suppress growth in C6 cells (a model of glioma) through 
treatment with forskolin, an AC activator, or a range of small molecule PDE inhibitors 
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with differing selectivity profiles. Forskolin suppressed cell growth in a PKA-dependent 
manner by inducing a G2/M phase cell cycle arrest. In contrast, trequinsin (a non-
selective PDE2/3/7 inhibitor), not only inhibited cell growth via PKA, but also stimulated 
(independent of PKA) caspase-3/-7 and induced an aneuploidy phenotype. 
Interestingly, a cocktail of individual PDE 2,3,7 inhibitors suppressed cell growth in a 
manner analogous to forskolin but not trequinsin. Finally, we demonstrate that 
concomitant targeting of both AC and PDEs synergistically elevated intracellular cAMP 
levels thereby potentiating their antiproliferative actions. 
 




Glioma is a general term for brain tumours that originate from glial cells in the central 
nervous system and which may progressively lead to death if not treated early [1, 2], 
with glioblastoma, the most common type of glioma, showing particularly poor survival 
[3]. The development of novel therapeutic approaches targeting glioma and 
glioblastoma are urgently required. 
Defects in a number of signalling pathways have been reported in glioma 
pathogenesis, including the phosphatidylinositol-3 kinases/ phosphatase and tensin/ 
protein kinase B/ mammalian target of rapamycin (PI3K/PTEN/Akt/mTOR) cascade; 
the retinoblastoma pathway (pRB); the Ras/ mitogen-activated protein kinase 
(RAS/MAPK) pathway; signal transducer and activator of transcription 3 (STAT3); zinc 
transporter 4 (ZIP4); as well as the adenylyl cyclase (AC) system [4].  
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Importantly, lower cAMP levels are observed in brain tumour tissue (25.8 
pmol/mg protein) compared to normal healthy tissue (98.8 pmol/mg protein) [5]. 
Indeed forskolin, an AC activator that elevates cAMP levels, has shown promising 
results in ameliorating cancer development [6]. While high levels of intracellular cAMP 
may kill cancer cells, the exact molecular mechanisms have not been clearly 
elucidated. Direct elevation of cAMP using the cAMP analogues 8-bromo-cAMP, 8-
chloro-cAMP, monobutyryl cAMP and dibutyryl cAMP, however, cannot be 
recommended due to the toxicity of these compounds [7]. Thus, there is a need to 
develop safe and effective compounds that can increase cAMP levels by 
pharmacological intervention. 
Depending on the cell type where the malfunctions are observed, cAMP may 
play a role in either promoting or suppressing cell proliferation. This incongruity can 
be explained by two theories on the cAMP signalling cascade. The first theory 
proposes that elevation of intracellular cAMP is beneficial for suppressing cell 
proliferation in most mesenchymal and epithelial cell lines, such as glioblastoma [8], 
thyroid cells [9], ovarian granulosa cells [10], fibroblasts [11], and primary 
cardiomyocytes [12]. In contrast, the second theory proposes that cAMP promotes cell 
survival, which has been observed in myeloid cells, pancreatic b-cells, hepatocytes, 
gastric and intestinal cells, spinal motor, superior cervical ganglion sympathetic, dorsal 
root ganglion, dopaminergic neurons, cerebral granule and septal cholinergic neurons 
[13]. These two divergent roles of cAMP may be crucial in both physiological 
maintenance and pathological conditions, but whether these signalling cascades are 
interconnected remains unclear.  
It has been well established that after synthesis by AC activation, cAMP diffuses 
within cells and is hydrolyzed to 5’AMP by phosphodiesterases (PDEs). PDEs are a 
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subfamily of ectonucleotidases consisting of 11 isoforms (PDE1–11) in mammals and 
are encoded by 21 different genes [14], which are distributed in many types of tissue 
[15]. Each isoenzyme possesses different affinities for cAMP and/or cGMP, kinetic 
characteristics, allosteric regulation by cAMP/cGMP and, phosphorylative control by 
various protein kinases, that result in their distinctive response to a stimulus [16, 17]. 
To date, there are 3 classes of PDEs subdivided according to their substrate 
specificities: cAMP-specific PDEs (PDE4, PDE7 and PDE8), cGMP-specific PDEs 
(PDE5, PDE6 and PDE9), and dual-substrate PDEs (PDE1, PDE2, PDE3, PDE10 and 
PDE11) [18]. Through metabolizing both cAMP and cGMP, PDEs generate 
intracellular gradients and microdomains of these second messengers to regulate their 
spatio-temporal signalling [19]. PDEs prevent non-specific activation, enabling both 
specificity and selectivity towards intracellular targets [20].  
Overexpression of some PDEs, such as PDE1, PDE4, PDE5, and PDE7, has 
been reported to alter patterns of cAMP in the brain [21-24]. Some evidence shows 
that particular PDE inhibitors, such as rolipram, a selective PDE4 inhibitor, prevents 
leukaemia proliferation through an elevation of cAMP and an induction of apoptosis. 
This suggests that using specific PDE inhibitors is a viable approach for cancer 
therapy [25]. Given that PDE inhibitors may offer therapeutic efficacy against cancer, 
we investigated the role of each PDE upon cAMP accumulation and cell proliferation 
in a glioma cell model using a range of pharmacological inhibitors. Our data indicates 
that tumour cell regression is linearly correlated with elevation of cAMP. Among all 
PDE inhibitors tested, trequinsin (a non-selective PDE2/3/7 inhibitor [26]) was found 
to be the most potent at inhibiting cell proliferation. More importantly, by using small 
molecule compounds we highlight that simultaneous elevation of cAMP through 
activation of AC and inhibition of multiple PDEs (specifically PDE2, PDE3 and PDE7) 
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had synergistic anti-proliferative effects on the glioma cells, predominantly by altering 
cell cycle progression and inducing activation of caspase-3/7, providing a novel 
treatment strategy for glioma.  
 
2. MATERIALS AND METHODS 
2.1 Cell Lines 
C6 glioma cells (a gift from Prof. Colin Taylor, University of Cambridge) were cultured 
in Gibco® Minimum Essential Medium (Thermo Fisher Scientific, UK) supplemented 
with 10% foetal bovine serum (FBS, Sigma, UK), 2 mM L-glutamine (Sigma, UK), and 
1% antibiotic/antimycotic (Sigma, UK). ST14A cells (rat-derived striatal cells (Tissue 
and Cell Biotechnologies, Italy) were grown in Gibco® DMEM/F12 1:1 (1X) – 
Glutamax TM (Thermo Fisher Scientific, UK), supplemented with 10% FBS and 1% 
antibiotic/antimycotic. C6 cells were maintained at 37 °C in humidified 95% air and 5% 
CO2. ST14A cells were grown at 33 °C in humidified 95% air and 5% CO2 because 
propagation of ST14A cells at 37 °C has been shown to induce differentiation into glial 
cells [27]. Where appropriate cells were treated with pertussis toxin (PTX, Thermo 
Fisher, UK) at a range concentration of 2 pg/ml to 200 ng/ml or cholera toxin (CTX, 
Sigma, UK), at a concentration of 3.5 pg/ml to 350 ng/ml. PTX uncouples receptor-
mediated Gαi-dependent inhibition of cAMP production, meanwhile CTX inhibits 
GTPase activity of Gas and causes permanent activation [28, 29]. 
 
2.2 Compounds 
Forskolin (Sigma, UK) was diluted to a stock of 100 mM in DMSO (Sigma, UK). 
Cholera toxin (CTX) was diluted in water to a stock of 35 μg/ml, whereas pertussis 
toxin (PTX) was diluted at a stock of 100 μg/ml. Isoprenaline hydrochloride (Sigma, 
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UK) was dissolved in water to a stock of 10 mM. Trequinsin, PF-2545920, vinpocetine, 
sildenafil, rolipram, cilostamide, caffeine, SQ22536, EHNA, amrinone, zaprinast, 
TC3.6, ibudilast, milrinone, BAY 73-6691, BRL-50481, piclamilast, IBMX, roflumilast, 
tadalafil, PF-04449613 (all purchased from Sigma, UK), BC 11-38, and PF 04671536 
(both obtained from Tocris, UK) were dissolved in DMSO to stock concentrations of 
either 100 mM or 10 mM. Guanylyl cyclase activators BAY 41-8543 and YC-1 were 
purchased from Tocris and diluted to a stock of 100 mM in DMSO. Exchange protein 
directly regulated by cAMP (Epac) inhibitors ESI-09, HJC0350, and CE3F4 (all 
purchased from Sigma, UK) were diluted to 10 mM stocks in DMSO. Protein kinase A 
(PKA) and protein kinase G (PKG) inhibitors, KT5720 and KT5823, respectively (all 
obtained from Cambridge Insight Biotechnology, UK) were diluted to stocks of 100 mM 
and 1 mM, respectively. MRP4 (multidrug resistant protein 4) inhibitor, PU23 (Tocris, 
UK), was dissolved in DMSO to a stock of 50 mM. 
 
2.3 Reverse Transcription PCR 
RNA was extracted from C6 and ST14A cells using RNAqueous®-4PCR Total RNA 
Isolation Kit (Life Technologies, UK) according to manufacturer’s instructions. In order 
to remove any contamination of genomic DNA, all RNA samples were treated with 
DNAse I included in the kit. The purity of RNA samples was quantified using a 
NanoDropTM Lite spectrophotometer (Thermo Scientific, UK) and only samples that 
had a minimum yield of 100 ng/µL and A260/280 >1.9 were used in the experiments. 
Complementary DNA was synthesized using a QuantiTect reverse transcription kit 
(Qiagen, UK). The oligonucleotides (Sigma, UK) used for PCR were designed 
specifically for rat, including GAPDH: forward 5′-TCCCTCAAGATTGTCAGCAA-3′, 
reverse 5′- AGATCCACAACGGATACATT-3′ (309 bp); PDE1A: forward 5′-
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CGCCTGAAAGGAATACTAAGA-3′, reverse 5′-TAGAAGCCAACCAGTCCCGGA-3′ 
(211 bp); PDE1B: forward 5′- CTGTCACCCCGCAGTCCTCCG-3′, reverse 5′-
GAAGGTGGAGGCCAGCCAGTC-3′ (309/306 bp); PDE1C forward 5′-
CGCGGGCTGAGGAAATATAAG-3′, reverse 5′-GAAGGTGGAGGCCAGCCAGTC-3′ 
(237 bp); PDE2A: forward 5′-CCAAATCAGGGACCTCATATTCC-3′, reverse 5′-
GGTGTCCCACAAGTTCACCAT-3′ (86 bp); PDE3A: forward 5′-
CACAAGCCCAGAGTGAACC-3′, reverse 5′-TGGAGGCAAACTTCTTCTCAG-3′ (123 
bp); PDE3B: forward 5′-GTCGTTGCCTTGTATTTCTCG-3′, reverse 5′-
AACTCCATTTCCACCTCCAGA-3′ (103 bp); PDE4A: forward 5′-
CGACAAGCACACAGCCTCT-3′, reverse 5′-CTCCCACAATGGATGAACAAT-3′ (73 
bp); PDE4B: forward 5′-CAGCTCATGACCCAGATAAGTGG-3′, reverse 5′-
GTCTGCACAAGTGTACCATGTTGCG-3′ (787 bp); PDE4C: forward 5′-
ATGGCCCAGATCACTGGGCTGCGG-3′, reverse 5′-
GCTGAGGTTCTGGAAGATGTCGCAG-3′ (582 bp); PDE4D: forward 5′-
CCCTCTTGACTGTTATCATGCACACC-3′, reverse 5′-
GATCCTACATCATGTATTGCACTGGC-3′ (262 bp); PDE5A: forward 5′-
CCCTGGCCTATTCAACAACGG-3′, reverse 5′-ACGTGGGTCAGGGCCTCATA-3′ 
(192 bp); PDE7A: forward 5′-GAAGAGGTTCCCACCCGTA-3′, reverse 5′-
CTGATGTTTCTGGCGGAGA-3′ (85 bp); PDE7B: forward 5′-
GGCTCCTTGCTCATTTGC-3′, 5′-GGAACTCATTCTGTCTGTTGATG-3′ (99 bp); 
PDE8A: forward 5′-TGGCAGCAATAAGGTTGAGA-3′, reverse 5′-
CGAATGTTTCCTCCTGTCTTT-3′ (97 bp); PDE8B: forward 5′-
CTCGGTCCTTCCTCTTCTCC-3′, 5′-AACTTCCCCGTGTTCTATTTGA-3′ (147 bp); 
PDE9A: forward 5′-GTGGGTGGACTGTTTACTGGA-3′, reverse 5′-
TCGCTTTGGTCACTTTGTCTC-3′ (107 bp); PDE10A: forward 5′-
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GACTTGATTGGCATCCTTGAA-3′, reverse 5′-CCTGGTGTATTGCTACGGAAG-3′ 
(115 bp); and PDE11A: forward 5′-CCCAGGCGATAAATAAGGTTC-3′, reverse 5′-
TGCCACAGAATGGAAGATACA-3′ (87 bp). 
 
All PCR products were run on a 2% agarose gel. The gel was visualised in the 
presence of ethidium bromide and imaged using a G Box iChemi gel documentation 
system. Density of each band was analysed with GeneTools analysis software 
(Syngene, UK). Correct band size was compared to that of previous works. 
 
2.4 cAMP accumulation assay 
Cells were grown to confluency in complete MEM growth medium. Cells were then 
trypsinised for 1 minute, re-suspended in stimulation buffer (PBS with 0.1% BSA) and 
plated onto 384-well optiplates (Perkin Elmer, UK) at a density of 2000 cells/well. To 
determine the efficacy of individual PDE inhibitors, cells were co-stimulated, 
immediately after seeding, with three different concentrations of compounds (which 
spanned 100-fold either side of the individual IC50 value in vitro) and pEC20 values of 
forskolin (1.6 µM for C6 cells and 50 nM for ST14A cells) for 30 minutes. Stimulating 
cells with the pEC20 of forskolin, enables a larger range to observe any effect of the 
PDE inhibitors on cAMP production. To generate full dose response curves, 
compounds were added to cells in the range of 0.1 pM – 100 µM for 30 minutes. 
Detection of cAMP was assessed using LANCE cAMP detection kit (Perkin Elmer, 
UK) and end-point measurement was performed using a Mithras LB940 microplate 
reader (Berthold Technologies, Germany). The lysed cells were excited at 340 nm 
wavelength with fluorescence from homogeneous time-resolved FRET detected at 
665 nm.  
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To determine the effects of G proteins on cAMP production, C6 cells were grown in 
complete MEM medium in the presence of either PTX or CTX for 16 hours (as a pre-
treatment). Subsequently, cells were dissociated using trypsin for 1 minute after which, 
complete medium was added to inactivate trypsin. Cells were washed, resuspended 
in PBS containing 0.1% BSA, and plated onto 384-well optiplates at a density of 8000 
cells/well. Total accumulation of cAMP was determined using the same protocol as 
described above. Data were either normalised to the maximal level of cAMP 
accumulation from cells in response to 100 μM forskolin stimulation or were 
interpolated to the cAMP standard curve and expressed as the concentration cAMP 
per 106 cells. Where stated, cAMP levels are quoted as pmoles per mg of protein 
mass, determined using Bradford protein assay (Biorad, UK) following the 
manufacturer’s instruction. 
 
2.5 Determination of intracellular and extracellular cAMP levels 
C6 cells were trypsinised and resuspended in PBS containing 0.1% BSA. 150,000 
cells were then treated with various concentrations of PU23 (10 μM, 3.16 μM, and 1 
μM, diluted in PBS containing 0.1% BSA) for 30 minutes. After treatment, cells were 
washed with PBS containing 0.1% BSA and stimulated with the pEC50 concentration 
of forskolin (3.16 μM), trequinsin (4.7 μM) or the PDE inhibitor cocktail (26 μM) for 1 
or 2 hours, in the presence or absence of each concentration of PU23. After 
stimulation, cells were centrifuged at 1677 x g for 4 minutes to separate supernatant 
and cell pellet. LANCE cAMP detection kit (Perkin Elmer, UK) was used to determine 
extracellular cAMP levels (supernatant) and intracellular cAMP levels (cell pellet). The 
concentration of cAMP was determined by interpolating the HTR-FRET values to the 
cAMP standard curve. cAMP levels are expressed as the concentration per 106 cells.  
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2.6 cGMP accumulation assay 
Confluent C6 cells were trypsinised and resuspended in PBS containing 0.1% BSA. 
Cells were plated onto a 384-well plate at a density of 500,000 cells/well and 
immediately stimulated with compounds for 30 minutes.  After stimulation, 5 µl of d2-
cGMP analogue and 5 µl mAb-cryptate were added to each well and incubated for 1 
hour at room temperature as per the manufacturer’s instruction (Cisbio, France). The 
d2-cGMP fluorophore was excited at a wavelength of 337 nm and emission was 
detected at 665 nm and 620 nm. Fluorescence was measured using a Mithras LB940 
microplate reader (Berthold Technologies, Germany). Delta F% values were 
calculated using the 665 nm/620 nm ratio and all data were interpolated to a standard 
curve which covered an average cGMP range of 0.5 – 50 nM. 
 
2.7 Cell proliferation assay 
C6 cells were seeded at a density of 2,500 cells/well in a clear flat bottom 96-well plate 
(Corning). After 24 hours, cells were exposed to test compounds or vehicle, in 
complete MEM growth medium, and were incubated for 72 hours. To further 
investigate whether downstream pathways of cAMP influenced cell proliferation, cells 
were cotreated with selective inhibitors that target cAMP/cGMP sensors including 
PKA, PKG, and Epac. Cells were seeded as previously described and treated with 
either forskolin or trequinsin in the presence of the following inhibitors: KT5720 to 
inhibit PKA, KT5823 to inhibit PKG, ESI-09 as non-selective Epac inhibitor, CE3F4 as 
a selective Epac1 inhibitor, and HJC0350 as a selective Epac2 inhibitor. In order to 
investigate the effect of blockade of cAMP export on cell proliferation, cells were 
treated with forskolin, trequinsin or PDE inhibitor cocktail in the presence, or absence, 
of various concentrations of PU23 (10 μM, 3.16 μM, and 1 μM). After 72 hours 
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incubation, 5 µL of Cell Counting Kit – 8 (CCK-8, Sigma, UK) was added to each well 
and the cells were incubated for an additional 2-3 hours at 37 °C in the dark. The 
absorbance of each well was measured using a Mithras LB940 microplate reader 
(Berthold Technologies, Germany) with an excitation of 450 nm. The amount of 
formazan formed is directly proportional to the number of viable cells. Cell proliferation 
was calculated as a percentage of number of cells treated with vehicle alone.  
 
2.8 Caspase assay 
C6 cells were seeded into clear bottom black 96-well plates (Corning) and treated with 
forskolin (1-100 µM), trequinsin (1-100 µM) or staurosporine (1 µM, a pan caspase 
activator) in complete MEM media. 1% DMSO was used as vehicle control. Cells were 
exposed to test compounds for 72 hours, plates were treated with 2 µM of the 
CellEventTMCaspase-3/7 green detection reagent (Life Technologies, UK) for 60 
minutes at 37 °C in the dark. Caspase activity was detected by cleavage of the 
tetrapeptide substrate DEVD, which is conjugated to a nucleic acid binding dye. 
Intracellular caspase-3/7 activities were imaged using a BD Pathway 855. To 
normalise the number of cells with caspase activated, cells were also labelled with 
Hoechst 33342 (Cambridge Bioscience, UK). Activated caspase-3/7 cleaves substrate 
and produce green fluorescence which was visualised using FITC/Alexa FluorTM 488 
filter setting. The total number of cells stained with Hoechst 33342 was measured 
using Hoechst filter (350/461 nm).  
 
2.9 Cell Cycle Analysis 
Cell cycle analysis using flow cytometry provides information on the distribution of cells 
in interphase stages of the cell cycle (G0/G1, S, and G2/M). C6 cells were seeded in to 
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24-well plates and cultured for 24 hours. Cells were exposed to selected treatments 
including forskolin, trequinsin, and a combination of individual PDE2,3,7 inhibitor, for 
72 hours. Subsequently, cells were harvested and resuspended in PBS containing 
0.1% Triton X-100, 10 µg/ml RNase A, and 5 µg/ml propidium iodide (PI) before 
incubation at 37 °C for 15 minutes. Samples were analysed using a BD Accuri C6 flow 
cytometer and cell cycle analysis was performed using BD C6 software. 
 
2.10 Statistical analysis 
To quantify gene expression through RT-PCR, the densitometry results of each gene 
of interest were normalised to GAPDH signal. For cAMP accumulation and cell 
proliferation assays, data were fitted to obtain concentration–response curves using 
the three-parameter logistic equation using GraphPad Prism 8 (GraphPad Software, 
San Diego) to obtain values of Emax /Imax, pEC50/pIC50, baseline, and span. Statistical 
differences were analysed using one-way ANOVA followed by Dunnett’s post-hoc (for 
comparisons amongst more than two groups) or independent Student’s t-test (for 
comparison between two groups). To determine the correlation of cAMP levels and 
cell proliferation of each PDE inhibitor in both C6 and ST14A cells, Pearson’s 
correlation coefficient (r) was calculated with 95% confidence interval. To compare the 
ability of compounds to suppress C6 cell proliferation a selection criterion was applied, 
whereby the term for affinity (pIC50) was multiplied by the term for efficacy (span). Error 












Where, SEMA and SEMB are the standard errors of the mean of measurement A and 
B with mean of 𝑥- and 𝑥3, 𝑥-3 is the composite mean. 
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3. RESULTS 
3.1 Elevation of cAMP levels reduces cell proliferation in a glioma cell line 
We first sought to determine if changes in cAMP concentration modulated glioma cell 
growth. When C6 cells, a rat-derived model for glioma, were exposed to the pan-AC 
activator, forskolin, we observed a dose-dependent increase in cAMP levels, up to 
34,566 ± 9,346 nM per 106 cells which equates to 484.23 ± 134.11 pmol cAMP/mg 
protein (lysed cells) (Fig. 1A, 1B), and reduced cell proliferation (Fig. 1D). 
Given the fact that there is crosstalk between the cAMP and cGMP pathways 
[30], we also evaluated the role of the cGMP pathway on cell proliferation by treating 
cells with the small molecule guanylyl cyclase activators, BAY 41-8543 and YC-1. Both 
compounds elevated cGMP levels (Fig. 1C), however, cGMP production was ~1000x 
lower than cAMP production in C6 cells, even in response to treatment with the nitric 
oxide (NO) donor, S-Nitroso-N-acetyl-DL-penicillamine (SNAP) (0.37 ± 0.04 pmol 
cGMP/mg protein). Surprisingly, both BAY 41-8543 and YC-1 also dose-dependently 
increased cAMP levels (Fig. 1A) but only ~20% relative to that of forskolin (Fig. 1A). 
BAY 41-8543 and YC-1 also had a minimal effect on cell proliferation compared to 
forskolin, with a reduction in cell survival only observed at 100 µM (Fig. 1D). These 
anti-proliferative effects may occur due to a modulatory effect between cAMP and 
cGMP. Accumulation of cGMP levels may lead to allosteric regulation of dual-
substrate PDEs leading to potentiation of cAMP and suppression of cell growth. These 
results suggest that that elevation cAMP pathway plays a more important role in 
reducing cell proliferation. 
Heterotrimeric G proteins are the primary effectors of G protein-coupled 
receptors (GPCRs) with Gas activating AC and Gai/o inhibiting AC [29]. Pertussis toxin 
(PTX) and cholera toxin (CTX) were utilised to determine whether G protein-mediated 
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cAMP production inhibits C6 cell growth. Treatment with CTX or PTX induced only a 
small elevation in cAMP levels and only suppressed C6 cell growth by 20% in a dose-
dependent manner (Fig. 1D). Furthermore, despite potent stimulation of cAMP 
accumulation upon treatment with the non-selective b-adrenoceptor agonist, 
isoprenaline, suppression of cell growth was significantly poorer than treatment with 
forskolin. This implies that GPCR-mediated cAMP accumulation is insufficient to 
maximally supress C6 cell growth and is likely a result of transient effector activation, 
receptor desensitisation or spatially localised signalling. Together, these results 
suggest that increasing cAMP concentration, through direct pharmacological 
activation of AC, plays a pivotal role in inhibiting cell growth with a minimal involvement 
of cGMP. 
3.2 Specific inhibition of PDEs indicates reliance on PDE expression levels 
Given that intracellular concentrations of cAMP are modulated both by its production 
and degradation, we next sought to investigate the expression of PDEs in a glioma 
cell line. Reverse transcription PCR (rt-PCR) was performed to determine the 
expression of each PDE isoenzyme in C6 cells, compared to ST14A cells, a rodent 
model for healthy neurons. As shown in Fig.  2, the overall expression level of PDEs 
was higher in C6 cells compared to ST14A cells. With the exception of PDE1C, there 
was little overall difference in the profiles of PDEs expressed between C6 cells and 
ST14A cells. PDE1C, PDE4D, PDE7A, and PDE7B were the only PDEs to display 
significant elevation in C6 cells.  
 The rt-PCR expression profiles showed a wide number of PDEs to be 
expressed in glioma cells. However, this was only semi-quantitative, thereby, not 
providing a clear indication as to which PDEs might be the most important. Thus, we 
next investigated the role of PDEs in regulating cAMP levels and cell proliferation in 
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C6 cells by applying small molecule selective PDE inhibitors as tools to modify their 
action. The small compounds were blindly screened and subsequently decoded after 
data analysis (see methods). Both cell lines were stimulated with the pEC20 
concentration of forskolin to increase the range for detecting an elevation of cAMP in 
the presence of selected PDE inhibitor. pEC50 values for cAMP production and pIC50 
values for cell growth inhibition for each compound are quoted in Table 1 and their 
pharmacological actions are summarised in Table 2. 
Plotting the potencies of each PDE inhibitor revealed a significant (p<0.001) 
positive correlation between elevation of cAMP levels and inhibition of cell growth (Fig. 
3A and 3B) for both C6 cells (r = 0.83 (95% confidence interval 0.46–0.95)) and ST14A 
cells (r = 0.97 (95% confidence interval (0.73–0.99)). To provide a convenient and 
rapid method for comparing each PDE inhibitor for effects on cell growth, the terms for 
efficacy and affinity (potency and span values) were multiplied for both C6 and ST14A 
cells (arbitrary units – Fig. 3C and 3D). An ideal compound would be one that shows 
high potency for inhibition of growth and a large range. An arbitrary threshold of 200 
was set to determine compounds that might be worth further investigation. Cisplatin, 
a widely used non-selective anti-proliferative agent, was used as a reference to 
validate our method (with pIC50 of 6.02 and 5.92 in C6 and ST14A cells, respectively, 
Table 1). In both C6 and ST14A cells, cisplatin showed the highest selection criteria 
value (582.1 in C6 cells and 511.1 in ST14A cells), thus proving that this calculation 
may help to determine how effective the compounds are at inhibiting cell proliferation. 
From our initial screen only 9 compounds were deemed to have passed the threshold: 
vinpocetine (PDE1 inhibitor), amrinone, milrinone (both PDE3 inhibitors), ibudilast 
(PDE4 inhibitor), trequinsin, IBMX and zaprinast (multiple PDE isoform inhibitors), 
BRL50481 (PDE7 inhibitor), and forskolin. The selectivity of the inhibitors that were 
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successful in the screen correlated well with PDE expression levels in C6 cells (Fig.  
2A and 2B). The compounds that showed the highest values (>350) were forskolin, 
trequinsin, amrinone, and IBMX. Apart from amrinone, these compounds target 
multiple components in the cAMP synthesis/degradation pathway, thus explaining 
their greater affinity/efficacy. IBMX and zaprinast were not used in future studies due 
to selectivity issues. IBMX is an adenosine receptor antagonist [31], whilst zaprinast 
is a GPR35 agonist [32]. Finally, it is worth noting that all compounds displayed lower 
affinity/efficacy values in ST14A cells (Fig. 3D) and this is consistent with the reduced 
PDE expression compared to C6 cells (Fig. 2B).  
 
3.3 Cocktail of individual PDE2, PDE3, and PDE7 inhibitors exhibited a similar 
effect to that of trequinsin, both upon elevating cAMP levels and suppressing 
cell growth  
Of all the compounds tested, trequinsin was the most potent at increasing cAMP levels 
and suppressing cell growth. Trequinsin is known to potently inhibit PDE3, but is 
suggested to also block the cAMP binding site of PDE2 and PDE7 [26]. This, however, 
has not been thoroughly investigated. Therefore, we probed the mechanism by which 
trequinsin exerts its antiproliferative effects by combining selective inhibitors against 
PDE2, PDE3, and PDE7 – by using EHNA, amrinone, and BRL-50481, respectively. 
 None of the selective PDE inhibitors were more potent at stimulating cAMP 
accumulation or inhibiting cell proliferation in C6 cells, as individual treatments, than 
trequinsin (Fig. 4A and 4D). Although amrinone displayed a similar Emax to that of 
trequinsin for cAMP accumulation, the Imax for cell growth inhibition was ~50% relative 
to trequinsin (Fig. 4A and 4D, Table 3). Subsequently, we investigated the 
combinatorial effect of individual PDE2, 3, and 7 inhibitors. The combination of EHNA 
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and amrinone (PDE2 and PDE3 inhibitors), as well as EHNA and BRL-50481 (PDE2 
and PDE7 inhibitors), enhanced the potency of effect compared to when these drugs 
were used individually (Fig. 4B and 4E, Table 3). However, the combination of BRL-
50481 with amrinone (PDE3 and PDE7 inhibitors) was comparable to that of amrinone 
alone. Interestingly, when all three selective inhibitors were combined, the potency 
and efficacy were similar to that of trequinsin (Fig. 4C and 4F, Table 3). Overall, this 
suggests that simultaneous inhibition of PDE2, PDE3, and PDE7 can mimic the 
antiproliferative effect of trequinsin. 
3.4 Targeting both AC and PDEs enhances the anti-proliferative effect  
Our data suggests that elevation of cAMP levels through either, activation of AC, or 
inhibition of PDEs, positively correlates with reduced cell proliferation. Thus, we 
hypothesised that dual activation of AC and inhibition of PDEs would induce larger 
suppression in cell growth beyond that of a single target treatment. To test this, we 
determined the combinatorial effect of forskolin and trequinsin on cAMP accumulation 
and cell proliferation (Fig. 5). 
There was a similar pattern of effects observed upon forskolin and trequinsin 
co-treatment on both cAMP accumulation and cell proliferation assays. The 
combination of forskolin and trequinsin significantly enhanced cAMP accumulation 
and reduced C6 cell growth in a dose-dependent manner compared to forskolin alone 
(Fig. 5A-C). The potency of the forskolin-mediated anti-proliferative effect was 
enhanced approximately 10-fold in the presence of 10 μM trequinsin (pIC50 of forskolin 
is 5.75, that of forskolin in combination with 10 μM trequinsin is 6.87). These data 
demonstrate synergistic elevation of cAMP by targeting AC and PDEs resulting in 
greater suppression of C6 cell growth. Indeed, the effect of the combination of 1 μM 
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forskolin and 0.1 μM trequinsin was approximately equal to that of cisplatin (pIC50 of 
6.09, Table 1).  
 
3.5 Blockade of cAMP export enhances the anti-proliferative effect of forskolin, 
trequinsin, and the PDE inhibitor cocktail 
C6 cells are known to express MRP4 [33] a transporter known to export intracellular 
cAMP. Having confirmed that inhibiting PDEs, or activating AC, elevates total cAMP 
levels and supresses proliferation of C6 cells, we aimed to investigate if these effects 
could be enhanced by preventing cellular export of cAMP.  
Pre-treatment with PU23, a small molecule inhibitor of MRP4, resulted in a 
dose-dependent reduction in extracellular cAMP levels post stimulation with forskolin, 
trequinsin or the PDE inhibitor cocktail (Fig.6A, C and D).  There was also a substantial 
elevation in intracellular concentrations of cAMP in the presence of PU23 after 2 hours 
stimulation with forskolin (Fig. 6B). This suggests that in the absence of PDE inhibitor, 
blockade of cAMP export maintains high intracellular cAMP levels. Indeed, the 
combination of PU23 with forskolin, trequinsin, or the PDE inhibitor cocktail enhanced 
the anti-proliferative effect of each compound (Fig.6 E-G). Taken together, these data 
suggest that suppression of C6 cell proliferation can be enhanced by blockade of 
cAMP export. 
 
3.6 The anti-proliferative effect of forskolin is mediated through a PKA-
dependent mechanism 
Having confirmed the effect of cAMP on C6 cell growth, we next wanted to 
investigate the involvement of downstream effectors of cAMP, such as PKA and Epac 
type I and II, as well as the cGMP effector, PKG, and GC activation on proliferation of 
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C6 cells (Fig. 7A). To do this, we utilised a range of small molecule inhibitors: KT5720 
(PKA), ESI-09 (non-selective Epac), CE3F4 (Epac1), HJC0350 (Epac2), and KT5823 
(PKG), and the GC activator (BAY 41-8543). Co-treatment of 10 µM KT5720 
significantly attenuated the anti-proliferative effects of forskolin (p<0.01), trequinsin 
(p<0.001) and the PDE inhibitor cocktail (p<0.05) on C6 cells (Fig. 7B-D).  None of the 
selective or non-selective Epac inhibitors had any effect on trequinsin-mediated cell 
growth suppression, although there was an elevation of forskolin-mediated cell growth 
suppression with CE3F4 (p<0.01) (Fig. 7B). Interestingly, cotreatment with KT5823 
significantly enhanced the anti-proliferative effects of forskolin and trequinsin 
(p<0.001), whilst BAY 41-8543 treatment also increased forskolin-mediated 
suppression of cell proliferation (p<0.01). This indicates an involvement of cGMP 
signalling pathways in cell proliferation. It is possible that accumulation of cGMP, in 
the presence of the PKG inhibitor or GC activator, potentiates cAMP/PKA signalling 
pathways through the sequestration of non-selective PDEs, thereby reducing cell 
growth. There was, however, no significant effect of BAY 41-8543 treatment on the 
anti-proliferative effects of trequinsin or the PDE inhibitor cocktail. This may suggest 
that the actions observed for KT5823 are not purely due to inhibition of PKG. These 
data highlight the importance of the homeostasis between cAMP and cGMP, as well 
as that the anti-proliferative effects of forskolin, trequinsin and the PDE inhibitor 
cocktail are largely mediated through a cAMP/PKA-dependent pathway.  
 
3.7 Trequinsin, but not forskolin or the PDE inhibitor cocktail, has cAMP-
independent actions leading to apoptosis  
In order to delineate the mechanism by which cAMP promotes cell death or inhibits 
cell growth, we investigated if the anti-proliferative effects on C6 cells were related to 
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apoptosis. Early apoptotic events can be detected through the protease activity of 
caspase-3 and caspase-7 that will eventually degrade proteins pivotal for cell survival. 
In this study, we quantified cells positive for caspase-3 and -7 activity in C6 cells using 
fluorescence microscopy after treatment with CellEventTM Caspase-3/-7 green 
detection kit. Cells were co-stained with Hoechst 33342 and propidium iodide to label 
all nuclei and dead cells. 
Staurosporine is a known pan caspase activator. Quantitative analysis revealed 
that staurosporine-treated cells were entirely positive for active caspase-3/-7 (Fig. 8A). 
Consistent with these results, activated caspase-3/-7 resulted in cell death which was 
confirmed by propidium iodide staining (Fig. 8A). Among all other treatments, only 100 
µM trequinsin exhibited comparable effects on cell death and caspase activity to that 
of staurosporine. Treatment with forskolin or the PDE 2,3,7 inhibitor cocktail resulted 
in less than 10% caspase activity and cell death (Fig. 7A). This suggests that 100 µM 
trequinsin may have toxic, non-cAMP-dependent effects, on C6 cells. 
 
3.8 Elevated intracellular cAMP induces growth arrest at the G2/M phase of the 
cell cycle 
Having demonstrated that elevation of cAMP inhibits cell proliferation, without inducing 
extensive apoptotic events on cells treated with forskolin, PDE inhibitor cocktail, or a 
low concentration of trequinsin, we postulated that this effect arose due to cell growth 
arrest. Thus, we investigated the individual stages of the cell cycle of C6 cells post-
treatment with forskolin, trequinsin or the PDE2,3,7 inhibitor cocktail by using 
propidium iodide staining and flow cytometry. Cell cycle analysis showed that 
forskolin, trequinsin, and the PDE2,3,7 inhibitor cocktail altered the cell phase (Fig. 
8B-E). While there was no significant difference between complete media and DMSO, 
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forskolin or PDE inhibitor cocktail treated cells arrested predominantly in G2/M phase. 
This indicates that both forskolin and the PDE2,3,7 inhibitor cocktail alter C6 cell cycle 
by a similar mechanism. In contrast, of the proportion of cells that survived treatment 
with 100 µM trequinsin, approximately 70% were aneuploid, with the remaining alive 
cells arrested in G2/M phase. Interestingly, when lower concentrations of trequinsin 
(<100 µM) were considered, the cell phase profile more closely matched that of 10 µM 
PDE2,3,7 inhibitor cocktail (Fig. 8B). This data suggests that 100 µM trequinsin 
induces a toxic effect on the C6 cells that is most likely independent of its action upon 
the cAMP pathway.  
 
4. DISCUSSION  
cAMP is a ubiquitous second messenger, which together with cGMP, controls a myriad 
of physiological responses [34] including reparative processes. Interestingly, cAMP 
signalling has been reported to have different effects on cell proliferation; either 
causing or arresting proliferation, depending on the cell type investigated [9, 13, 35]. 
These divergent effects of cAMP on the proliferative response are believed to be 
controlled by several factors including stimulus, the nature of the intracellular cAMP 
effectors within the cells, the strength of signal, and subcellular compartmentalisation 
[36]. In brain tumours, suppression of cAMP is associated with gliomagenesis 
compared to non-tumour controls [37, 38]. As cAMP levels are suppressed 4-fold in 
brain tumours compared to those in normal tissue [5], we hypothesised that 
augmenting production of cAMP may restore intracellular signalling and have 
beneficial antiproliferative effects.  
Although PDEs have long been targets for pharmacological modulation, there 
have been no studies characterising PDE isoenzyme expression in glioma cells or the 
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effect of PDE modulation. In the present study, we demonstrate that direct 
pharmacological activation of AC and inhibition of PDEs results in greater suppression 
of glioma cell proliferation than G protein-mediated AC activation. Although activation 
of Gs-coupled b-ARs by isoprenaline, or modulation of G protein activity by PTX or 
CTX treatment increased cAMP production, neither substantially suppressed glioma 
cell growth. This is possibly due to only transient activation of cAMP effectors, receptor 
desensitisation, spatially localised cAMP accumulation, or, the instability of 
isoprenaline in aqueous solution. Prolonged stimulation with GPCR agonists not only 
induces desensitisation through receptor internalisation, but may also alter 
transcription levels resulting in receptor downregulation [39]. It is worth noting that 
addition of antioxidant such as ascorbic acid or EDTA may be useful to minimise the 
degradation of isoprenaline during the treatment.  
Evaluation of PDE mRNA expression level in C6 cells revealed that almost all 
PDE isoenzymes are expressed. Interestingly, inhibitors of cAMP-specific or cGMP-
specific PDEs showed minimal effects on cell growth, except for ibudilast (a cAMP-
specific PDE4 inhibitor). Inhibition of PDE1, PDE2, PDE3, PDE4, and PDE7 resulted 
in greater modulation of cAMP levels and cell growth. These PDEs, with the exception 
of PDE4 and PDE7, hydrolyse both cAMP and cGMP. Dual substrate PDEs provide a 
point for crosstalk between cGMP and cAMP signalling pathways and have unique 
mechanisms of regulation [40, 41].  
The most potent anti-proliferative effects were observed in trequinsin-treated 
cells. Trequinsin is commonly known as an ultrapotent PDE3 inhibitor, although it has 
also been shown to have activity against PDE2 and PDE7 [26]. There have, however, 
been no studies into inhibition of PDE2 and PDE7 by trequinsin. A combination of 
inhibitors of PDE2, PDE3, and PDE7, the PDE inhibitor cocktail, had a similar 
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magnitude of effect to that of trequinsin, whilst inhibition of single or dual PDEs failed 
to mimic the effect. In order to enhance antiproliferative activity further, the selectivity 
of individual compounds towards each PDE needs to be improved. 
Through the use of several pharmacological tools we attributed forskolin and 
trequinsin, and the PDE inhibitor cocktail mediated inhibition of cell growth to 
enhanced activation of PKA. Considering the greater affinity of cAMP for PKA than 
Epac1/2 (5-24.6 nM versus 4 µM/1.2 µM, respectively) [42-44], it is possible that 
elevated cAMP, upon treatment with forskolin or PDE inhibitors will preferentially 
activate PKA over Epac1/2. Taken together, there is a possibility that stimulation of 
AC by forskolin or by PDE inhibitors will trigger massive production of cAMP and 
consequently the PKA pathway will be predominantly activated with minor involvement 
of Epac1/2. The inhibitory action of cAMP on cell growth has also been reported to 
involve a complex mechanism between PKA, MAPK/ERK, and cyclin-dependent 
kinase 2 [45, 46].  
Somewhat unexpectedly, this study demonstrated that PKG inhibition 
increased the anti-proliferative effects of forskolin- and trequinsin- treated cells, whilst 
GC activation also potentiated forskolin-mediated cell growth suppression. This is 
most likely due to cross talk between the cGMP and cAMP pathways via dual substrate 
PDEs. For instance, while cGMP binding to PDE2 allosterically enhances hydrolysis 
of cAMP, cGMP competitively inhibits PDE3 to reduce the rate of cAMP breakdown . 
This control is, however, dependent on the concentration of cGMP, with allosteric 
regulation of PDE2 requiring higher (1-5 µM) [47] cGMP levels than the affinity of 
cGMP for the catalytic site of PDE3 (180 nM) [17]. We have shown that C6 cells have 
a weaker propensity to elevate cGMP levels than cAMP. Thus, a modest increase in 
cGMP may compete with cAMP to occupy catalytic sites resulting in a decrease in the 
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hydrolysis rate of cAMP by dual substrate PDE isoforms, thus activating the 
cAMP/PKA pathway triggering enhanced cell growth suppression.  
Surprisingly, there was no effect of PKG inhibition or GC activation on the anti-
proliferative effects of the PDE inhibitor cocktail. Whilst this may suggest that the 
actions observed for KT5823 are not purely due to inhibition of PKG the functional 
effect of the PDE inhibitor cocktail may be affected by compartmentalisation and local 
activation of PKA. A small increase in cGMP may elevate cAMP levels only in distinct 
subcellular regions in the presence of the PDE inhibitor cocktail to activate PKA 
through anchoring proteins (AKAP) to different intracellular microstructures [47]. 
Although further investigation is required, these phenomena can be taken into account 
in explaining the differential responses observed upon PDE inhibitor cocktail 
treatment.  
 Although trequinsin has a comparable potency to that of forskolin for elevating 
intracellular cAMP levels and supressing cell proliferation, at high concentrations (100 
µM) trequinsin induced substantial cell death of C6 cells and ST14A cells. This implies 
that at such high concentrations trequinsin binds to other non-PDE proteins that results 
in direct activation of caspase-3/7 to trigger cell death. Adequate activation of PKA will 
activate p53 and induce apoptosis [48] although we observed only less than 10% cell 
death. Nonetheless, the remaining cells were aneuploidy with at least 4N. It is likely 
that cells underwent faulty cell division and were not able to exit the mitotic state due 
to rapid and massive elevation of cAMP by 100 μM trequinsin. There are no studies 
on the mechanism by which trequinsin causes aneuploidy and apoptosis, however, 
there are several reports that in other types of cancer where cAMP levels are elevated 
by PDE inhibition, activation of PKA resulted in activation of protein phosphatase 2A 
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(PP2A) and Bim/BAD expression [13] that eventually cleaves caspases to mediate 
apoptosis.  
Despite this, the study demonstrates that multitarget enhancement of cAMP 
signalling elevates anti-proliferative effects in a glioma cell model. Increasing cAMP 
levels through activation of AC (forskolin) and multiple PDE inhibition (by trequinsin) 
demonstrated synergistic cell growth suppression. Similarly, whilst it has been 
suggested that cyclic nucleotide efflux pumps may not contribute to controlling cAMP 
signalling [49], our study shows that inhibiting export of cAMP significantly enhances 
forskolin and multiple PDE inhibition mediated cell growth suppression. Thus, the dose 
of each compound could be reduced to potentially prevent any toxic side effects from 
trequinsin. Alternatively, combining individual selective inhibitors against PDE2,3,7 
together showed similar efficacy to that of trequinsin but without significant toxicity in 
glioma cells. The inhibitor cocktail shows a higher number of cells with active caspase-
3/7 activity compared to forskolin, possibly due to the availability of PDEs, which have 
been shown to be caspase substrates [13]. Both forskolin and the inhibitor cocktail 
trapped cells in G2/M phase, which may lead to the loss of essential cellular 
components that are required for replication. Whilst this study has demonstrated that 
targeting the cyclic nucleotide pathway can suppress C6 cell growth, it should be noted 
that PDEs play an important role in many systems throughout the body, including the 
cardiovascular system, and thus targeting PDEs may cause off-target effects.  
In conclusion, we have used a chemical biology approach to demonstrate that 
cAMP inhibits growth of glioma cells. Anti-proliferative effects of forskolin are mediated 
by elevating cAMP levels leading to activation of PKA and arrest of cells in the G2/M 
phase of the cell cycle. In comparison, multiple inhibition of PDEs by trequinsin not 
only inhibits cell growth via the cAMP/PKA cascade, but also triggers cell death 
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through caspase-3/-7 activation. Concomitant targeting of both AC and PDEs 
synergistically elevates intracellular cAMP levels within glioma cells. Due to possible 
side effects of trequinsin, a cocktail of individual PDE2, PDE3, and PDE7 inhibitors 
can be used as an alternative to trequinsin to obtain similar functional effects without 
any toxicity. This study offers insight to identify new therapeutic approaches which 
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Fig. 1. Elevation of cAMP, but not cGMP, mediates cell growth suppression. 
A. cAMP levels following 30 minutes treatment with adenylyl cyclase activator 
(forskolin) or guanylyl cyclase activators (YC-1 and BAY 41-8543). B-C. 
Comparison of accumulation of cAMP and cGMP in C6 cells in response to 
forskolin (100 µM), BAY 41-8543 (100 µM), YC-1 (100 µM), or SNAP (100 µM). 
Survival of C6 cells following 72 hours treatment with forskolin, BAY 41-8543 or 
YC-1 (D) or PTX or CTX (E). F. cAMP levels after 16 hours pre-treatment with PTX 
or CTX in comparison to untreated cells. G. cAMP levels in C6 cells following 30 
minutes stimulation with forskolin or the non-selective beta-adrenergic agonist, 
A. B.
D. E.



























































































































































































































































































isoprenaline. Data are expressed relative to 100 µM forskolin H. Cell survival of C6 
cells following 72 hours treatment with forskolin or isoprenaline. Data are 
expressed as percentage survival relative to vehicle alone and are the mean±SEM 
of 6-9 individual experiments. Statistical significance was determined using a one-


















Fig. 2. Expression profile of PDE isoenzymes in C6 and ST14A cells. A. 
Representative gel documentation showing amplified PDEs genes from C6 and 
ST14A cell line. (*) on the gel showed correct band size. B. Semi-quantitative mRNA 
levels in C6 cells and ST14A cells. Expression of each gene of interest was normalised 
relative to GAPDH. Data are expressed as the mean ± SEM from 5-7 individual 





































































































































































































95% CI = 0.73 - 0.99
























































































































































































































































































































































Fig. 3. Elevation of intracellular cAMP is positively correlated with cell growth 
suppression. A-B. Correlation (with 95% confidence interval) of log potencies of each 
PDE inhibitor in C6 (A) and ST14A cells (B) was determined by calculating Pearson’s 
correlation coefficient (r). C-D. Compound selection criteria from C6 (C) and ST14A 
cells (D) was calculated based on potency and efficacy in proliferation assay. The 
dashed lines represent threshold value of 200 (less stringent criteria) and the dotted 
lines a higher criteria value of 350. Individual data point was obtained from 


















Fig. 4. The effect of selective PDE inhibitors, as individual, dual, or multiple 
treatments, on intracellular cAMP levels and cell proliferation in C6 glioma cells. 
A-C. cAMP accumulation was determined in C6 cells following 30 min stimulation with 
EHNA, Amrinone or BRL-50481 alone (A), in pairs (B), or combined (C). Data are 
expressed relative to 100 µM forskolin. D-F. Cell survival was determined in C6 cells 
following 72 hours incubation with EHNA, Amrinone or BRL-50481 alone (D), in pairs 
(E), or combined (F). Data are expressed as percentage of cell survival relative to 
vehicle from 6-9 data sets. The effect of trequinsin alone is displayed on each graph 
for comparison.  All data are the mean ± SEM of 6–9 individual repeats.  
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Fig. 5.  Forskolin and trequinsin act synergistically to increase cAMP 
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trequinsin upon cAMP accumulation in C6 cells following 30 min stimulation with 
forskolin. Data are expressed relative to 100 µM forskolin in the absence of trequinsin. 
B. Concentration-dependent inhibitory effect of trequinsin on C6 cell growth following 
72-hour incubation with forskolin. Data are expressed as percentage cell survival 
relative to vehicle. C. pIC50 values for individual cell survival curves for each treatment 
condition. All data are the mean ± SEM of 6-9 individual repeats. Data were 
determined as statistically different (ns, not significant; ***, p<0.001) compared to 

















Fig.6. Elevation of intracellular cAMP by inhibiting its efflux is correlated with 
cell growth suppression in C6 cells. A-D. Extracellular and intracellular cAMP levels 
from C6 cells following stimulation with; forskolin for 1h (A) and 2h (B); trequinsin for 
2h (C); or PDE inhibitor cocktail for 2h (D), in the presence and absence of a range of 
concentrations of the MRP4 inhibitor, PU23. E-G. Survival of C6 cells following 72-
hour treatment with forskolin (E), trequinsin (F), or PDE inhibitor cocktail (G) in the 
absence and presence of increasing concentrations of PU23. Data are expressed as 
percentage cell survival relative to vehicle. All data are the mean ± SEM of 4-8 
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Fig. 7. The effect of downstream effectors of cAMP and cGMP on forskolin and 
trequinsin-mediated cell growth suppression of C6 cells. A. Schematic diagram 
illustrating cAMP and cGMP synthesis, degradation and downstream effectors. B-D. 
Cell survival was determined in C6 cells following 72 hours incubation with forskolin 
(B), trequinsin (C), or a combination of PDE2,3,7 inhibitors (D) in the presence either 
KT5720 (10 µM) , ESI-09 (10 µM), CE3F4 (10 µM), HJC0350 (10 µM), KT5823 (10 
µM), BAY41-8543 (10 µM). Data are represented as individual pIC50 values for anti-
proliferation curves for each treatment condition. Data were determined as statistically 
different (ns, not significant; *, p< 0.05; **, p<0.01; ***, p<0.001) compared to in the 
absence of compounds using one-way ANOVA followed by Dunnett’s post-hoc 
analysis. KT5720 – PKA inhibitor, ESI-09 - non-selective Epac1/2 inhibitor, CE3F4 – 





























+ + + + + +
- + - - - -
- - + - - -
- - - + - -
- - - - + -









































+ + + + + +
- + - - - -
- - + - - -
- - - + - -
- - - - + -
- - - - - +






































+ + + + + +
- + - - - -
- - + - - -
- - - + - -
- - - - + -
- - - - - +











Fig. 8. Population of dead cells and activity of caspase-3/7 in C6 cells after 72 h 






































































































































Percentage of dead cells determined by staining with propidium iodide and the 
percentage of cells with activated caspase-3/7, visualised by CellEvent caspase-3/7. 
All values are normalised to total cell number in each well. Staurosporine 1 µM was 
used as a control for apoptotic cell death and cause 100% dead cells. B. 
Representative histograms of cell cycle distribution of C6 cells with selected treatment. 
C-E. Representative histograms of cells following treatment with forskolin (C), 
trequinsin (D), or PDE2,3,7 inhibitor cocktail (E) for 72 h. The percentage of cell 
distribution for each treatment including G1, S, G2/M, and dead cell population (n= 4-
8 individual data). All data are the mean ± SEM of 5 individual repeats. Data were 
determined as statistically different (*, p<0.05; **, p<0.01; ***, p<0.001) compared to 
1% DMSO using a one-way ANOVA followed by Dunnett’s post hoc analysis. * p<0.05, 







Table 1.  
Potency values for cAMP production (pEC50) and for cell growth inhibition (pIC50) of each PDE inhibitor in C6 glioma cells 
and ST14A cells.  
  C6 ST14A 
Compounds Target 
PDE(X) ¥ 
pEC50 Span (cAMP) pIC50 Span 
(proliferation) 
pEC50 Span (cAMP) pIC50 Span 
(proliferation) 
Vinpocetine  1 15.10 ± 0.08*** 27.86 ± 1.05*** 5.83 ± 0.13* 45.33 ± 3.12*** 4.16 ± 0.04***  13.15 ± 2.22*** N/A N/A 
EHNA 2 15.06 ± 0.07*** 24.26 ± 1.78***    5.04 ± 0.25 36.34 ± 3.31*** N/A  N/A    6.57 ± 0.08*** 20.86 ± 1.20*** 
Cilostamide  3 17.19 ± 0.09*** 15.20 ± 1.45*** N/A N/A N/A N/A   8.39 ± 0.15*** 10.56 ± 1.90*** 
Amrinone 3 13.68 ± 0.08*** 108.9 ± 4.82***   4.11 ± 0.04*** 86.44 ± 2.26***  3.84 ± 0.02***   89.70 ± 1.12**   3.91 ± 0.11*** 54.37 ± 6.17*** 
Milrinone  3 N/A N/A   8.06 ± 0.13*** 34.49 ± 4.66***  7.05 ± 0.18***   27.45 ± 2.35 N/A N/A 
Trequinsin 2,3,7 15.65 ± 0.08*** 50.57 ± 2.02*** 4.87 ± 0.07* 96.93 ± 0.94***  6.21 ± 0.06***   80.31 ± 1.85    4.62 ± 0.04*** 75.82 ± 0.79*** 
Rolipram  4 16.96 ± 0.04*** 60.46 ± 3.74***   6.78 ± 0.20*** 23.44 ± 2.94***  7.41 ± 0.04***   59.26 ± 4.11**  7.23 ± 0.05*** 15.57 ± 1.28*** 
Ibudilast  4 16.03 ± 0.11*** 64.21 ± 3.46***   7.05 ± 0.17*** 31.76 ± 1.30***  6.15 ± 0.12***  48.64 ± 2.18*** N/A N/A 
Piclamilast  4 18.72 ± 0.04*** 41.32 ± 2.87*** N/A N/A  9.02 ± 0.14***  35.24 ± 1.96*** N/A N/A 
Roflumilast  4 10.47 ± 0.03*** 54.58 ± 3.12*** 10.57 ± 0.22*** 14.72 ± 1.66*** 10.48 ± 0.08***  28.77 ± 0.78*** 10.92 ± 0.09*** a7.19 ± 1.63*** 
Sildenafil  5 N/A N/A   8.56 ± 0.16*** -6.77 ± 3.54***#  8.79 ± 0.20***   -4.57 ± 0.93***#   9.67 ± 0.11*** 12.71 ± 2.02*** 
Tadalafil  5 N/A N/A N/A N/A   7.88 ± 0.04*** -23.15 ± 1.38***#   8.81 ± 0.43*** -2.69 ± 1.55***# 
Caffeine  1,4,5 N/A N/A N/A N/A N/A N/A   6.65 ± 0.06 *** a9.02 ± 1.08*** 
Zaprinast  5,6,9,11 5.61 ± 0.11*** 14.27 ± 1.12***   6.03 ± 0.30*** 49.70 ± 4.60*** N/A N/A    5.86 ± 0.09*** 46.71 ± 1.45*** 
TC3.6 7 N/A N/A   7.53 ± 0.26*** 15.31 ± 2.47*** N/A  N/A   5.69 ± 0.05*** 21.22 ± 1.49*** 
BRL-50481 7 a6.41 ± 0.09*** 31.3 ± 1.67***   6.70 ± 0.15 *** 33.07 ± 2.74*** N/A  N/A    7.73 ± 0.24*** a4.52 ± 1.68*** 
BC 11-38 8 N/A N/A N/A N/A N/A N/A N/A N/A 
BAY-736691 9 N/A N/A N/A N/A N/A N/A N/A N/A 
PF-0449613 9 N/A N/A N/A N/A 7.55 ± 0.12*** -23.48 ± 1.75***#   8.05 ± 0.08*** a6.37 ± 0.72*** 
PF 2545920 10A N/A N/A  9.46 ± 0.06*** -8.97 ± 3.05#*** N/A N/A 10.78 ± 0.11*** 11.94 ± 4.13*** 
PF 04671536 11 N/A N/A N/A N/A N/A N/A N/A N/A 
IBMX  Non-
selective a4.30 ± 0.06
*** 42.79 ± 1.53*** 6.12 ± 0.06*** 54.17 ± 3.20***  4.56 ± 0.06***   57.53 ± 3.52    4.20 ± 0.09 47.95 ± 2.70 
Forskolin AC activator a5.43 ± 0.08*** 64.97 ± 3.51*** 5.12 ± 0.06*** 84.70 ± 1.44***    6.43 ± 0.12   74.06 ± 3.07    6.44 ± 0.02   45.11 ± 1.22 
Cisplatin DNA 
crosslinker 
N/A N/A 6.02 ± 0.09*** 96.85 ± 2.57  N/A N/A    5.92 ± 0.09*** 86.50  ± 2.30*** 
N/A – not applicable; compounds did not have any effect on cAMP production or cell growth inhibition. ¥, unless mentioned, targets 
refer to particular PDE isoform. Data are presented as the mean ± SEM of 6-9 individual repeat. Data were determined as statistically 
different (*, p<0.05; ***, p<0.001) compared to forskolin using one-way ANOVA followed by Dunnett’s post-hoc analysis. #, showing 
negative responses, either suppressing cAMP accumulation or being proliferative. 
Table 2.  
Summary of the pharmacological effects of each PDE inhibitor on cAMP 
production and cell proliferation 
Compound Target C6 ST14A 
cAMP Proliferation cAMP Proliferation 
Vinpocetine 1 ­ ¯¯ ­ - 
EHNA 2 ­ ¯¯ - ¯ 
Cilostamide 3 ­ - - ¯ 
Amrinone 3 ­­­ ¯¯¯ ­­­ ¯¯¯ 
Milrinone 3 - ¯¯ ­ - 
Trequinsin 2,3,7 ­­­ ¯¯¯ ­­­ ¯¯¯ 
Rolipram 4 ­­­ ¯ ­­­ ¯ 
Ibudilast 4 ­­­ ¯¯ ­­ - 
Piclamilast 4 ­­ - ­­ - 
Roflumilast 4 ­­­ ¯ ­ ¯ 
Sildenafil 5 - ­ ¯ ¯ 
Tadalafil 5 - ­ ¯ ­ 
Caffeine 1,4,5 Bell-shape - - ¯ 
Zaprinast 5,6,9,11 ­ ¯¯ - ¯¯ 
TC3.6 7 - ¯ - ¯ 
BRL-50481 7 ­­ ¯¯ - ¯ 
BC 11-38 8 - - - - 
BAY-736691 9 - - - - 
PF-0449613 9 - - ¯ ¯ 
PF 2545920 10A - ­ - ¯ 
PF 04671536 11 - - - - 
IBMX Non-
selective 
­­ ¯¯¯ ­ ¯¯ 
­ = increase 10-30%, ­­ = increase 31-50%, ­­­= increase >50%, ¯: suppress 10-
30%, ¯¯: suppress 31-50%, ¯¯¯: suppress >50% 
Table 3. 
C6- proliferation assay-combinatorial effect of PDE2, 3, 7 inhibitors  
 
Compound cAMP accumulation assay  Proliferation Assay Selection 
criteria* pEC50 Span pIC50 Span 
Trequinsin 5.33 ± 0.11 46.31 ± 1.98 4.52 ± 0.11  91.21 ± 8.26 411.94 ± 38.52 
EHNA 4.91 ± 0.10 26.19 ± 0.89 4.20 ± 0.21 57.21 ± 10.48 240.44 ± 45.57 
Amrinone 4.58 ± 0.04 53.88 ± 1.63 3.94 ± 0.15 87.79 ± 13.62 346.01 ± 55.26 
BRL-50481 6.20 ± 0.34 13.86 ± 0.74 4.79 ± 0.17 47.02 ± 4.45 225.39 ± 22.73 
EHNA + amrinone 
4.58 ± 0.03 62.51 ± 2.17 4.19 ± 0.17 85.97 ± 12.32 
 
361.56 ± 53.66 
EHNA + BRL-
50481 5.05 ± 0.20 27.21 ± 1.40 4.07 ± 0.13  77.77 ± 9.73 
 
316.34 ± 40.85 
Amrinone + BRL-
50481 4.65 ± 0.07 49.65 ± 2.95 3.77 ± 0.17 66.75 ± 11.94 
 
248.98 ± 45.30 
EHNA + amrinone 
+ BRL-50481 4.58 ± 0.07 64.97 ± 1.82 4.52 ± 0.14  84.64 ± 8.69 
 
382.12 ± 41.10 
 
Data are expressed as mean ± SEM from 7-10 individual data.  
* Compound selection criteria was calculated based on potency and efficacy in 
proliferation assay (data obtained from Figure 4). 
 
Table 1.  
Potency values for cAMP production (pEC50) and for cell growth inhibition (pIC50) of each PDE inhibitor in C6 glioma cells 
and ST14A cells.  
  C6 ST14A 
Compounds Target 
PDE(X) ¥ 
pEC50 Span (cAMP) pIC50 Span 
(proliferation) 
pEC50 Span (cAMP) pIC50 Span 
(proliferation) 
Vinpocetine  1 15.10 ± 0.08*** 27.86 ± 1.05*** 5.83 ± 0.13* 45.33 ± 3.12*** 4.16 ± 0.04***  13.15 ± 2.22*** N/A N/A 
EHNA 2 15.06 ± 0.07*** 24.26 ± 1.78***    5.04 ± 0.25 36.34 ± 3.31*** N/A  N/A    6.57 ± 0.08*** 20.86 ± 1.20*** 
Cilostamide  3 17.19 ± 0.09*** 15.20 ± 1.45*** N/A N/A N/A N/A   8.39 ± 0.15*** 10.56 ± 1.90*** 
Amrinone 3 13.68 ± 0.08*** 108.9 ± 4.82***   4.11 ± 0.04*** 86.44 ± 2.26***  3.84 ± 0.02***   89.70 ± 1.12**   3.91 ± 0.11*** 54.37 ± 6.17*** 
Milrinone  3 N/A N/A   8.06 ± 0.13*** 34.49 ± 4.66***  7.05 ± 0.18***   27.45 ± 2.35 N/A N/A 
Trequinsin 2,3,7 15.65 ± 0.08*** 50.57 ± 2.02*** 4.87 ± 0.07* 96.93 ± 0.94***  6.21 ± 0.06***   80.31 ± 1.85    4.62 ± 0.04*** 75.82 ± 0.79*** 
Rolipram  4 16.96 ± 0.04*** 60.46 ± 3.74***   6.78 ± 0.20*** 23.44 ± 2.94***  7.41 ± 0.04***   59.26 ± 4.11**  7.23 ± 0.05*** 15.57 ± 1.28*** 
Ibudilast  4 16.03 ± 0.11*** 64.21 ± 3.46***   7.05 ± 0.17*** 31.76 ± 1.30***  6.15 ± 0.12***  48.64 ± 2.18*** N/A N/A 
Piclamilast  4 18.72 ± 0.04*** 41.32 ± 2.87*** N/A N/A  9.02 ± 0.14***  35.24 ± 1.96*** N/A N/A 
Roflumilast  4 10.47 ± 0.03*** 54.58 ± 3.12*** 10.57 ± 0.22*** 14.72 ± 1.66*** 10.48 ± 0.08***  28.77 ± 0.78*** 10.92 ± 0.09*** a7.19 ± 1.63*** 
Sildenafil  5 N/A N/A   8.56 ± 0.16*** -6.77 ± 3.54***#  8.79 ± 0.20***   -4.57 ± 0.93***#   9.67 ± 0.11*** 12.71 ± 2.02*** 
Tadalafil  5 N/A N/A N/A N/A   7.88 ± 0.04*** -23.15 ± 1.38***#   8.81 ± 0.43*** -2.69 ± 1.55***# 
Caffeine  1,4,5 N/A N/A N/A N/A N/A N/A   6.65 ± 0.06 *** a9.02 ± 1.08*** 
Zaprinast  5,6,9,11 5.61 ± 0.11*** 14.27 ± 1.12***   6.03 ± 0.30*** 49.70 ± 4.60*** N/A N/A    5.86 ± 0.09*** 46.71 ± 1.45*** 
TC3.6 7 N/A N/A   7.53 ± 0.26*** 15.31 ± 2.47*** N/A  N/A   5.69 ± 0.05*** 21.22 ± 1.49*** 
BRL-50481 7 a6.41 ± 0.09*** 31.3 ± 1.67***   6.70 ± 0.15 *** 33.07 ± 2.74*** N/A  N/A    7.73 ± 0.24*** a4.52 ± 1.68*** 
BC 11-38 8 N/A N/A N/A N/A N/A N/A N/A N/A 
BAY-736691 9 N/A N/A N/A N/A N/A N/A N/A N/A 
PF-0449613 9 N/A N/A N/A N/A 7.55 ± 0.12*** -23.48 ± 1.75***#   8.05 ± 0.08*** a6.37 ± 0.72*** 
PF 2545920 10A N/A N/A  9.46 ± 0.06*** -8.97 ± 3.05#*** N/A N/A 10.78 ± 0.11*** 11.94 ± 4.13*** 
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negative responses, either suppressing cAMP accumulation or being proliferative. 
Percentage of dead cells determined by staining with propidium iodide and the 
percentage of cells with activated caspase-3/7, visualised by CellEvent caspase-3/7. 
All values are normalised to total cell number in each well. Staurosporine 1 µM was 
used as a control for apoptotic cell death and cause 100% dead cells. B. 
Representative histograms of cell cycle distribution of C6 cells with selected treatment. 
C-E. Representative histograms of cells following treatment with forskolin (C), 
trequinsin (D), or PDE2,3,7 inhibitor cocktail (E) for 72 h. The percentage of cell 
distribution for each treatment including G1, S, G2/M, and dead cell population (n= 4-
8 individual data). All data are the mean ± SEM of 5 individual repeats. Data were 
determined as statistically different (*, p<0.05; **, p<0.01; ***, p<0.001) compared to 
1% DMSO using a one-way ANOVA followed by Dunnett’s post hoc analysis. * p<0.05, 
** p<0.005, *** p<0.001. FSK – forskolin, TRQ – trequinsin, STR – staurosporine. 
 
 
 
 
 
 
